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Cesarean scar ectopic pregnancy is a rare type of ectopic pregnancy with high 
morbidity and mortality. Use of conservative conducts, including medical man-
agement with methotrexate, has avoided mutilating surgeries such as hysterec-
tomy and spared the fertility of women. We report the case of a 30-year old pa-
tient with a cesarean scar ectopic pregnancy, with a live embryo, who was 
treated locally with transvaginal ultrasound-guided injection of methotrexate, 
complemented with various doses of systemic methotrexate.
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introduction
Non-tubal ectopic pregnancies represent less than 10% 
of all ectopic pregnancies, but are associated with high 
morbidity.1,2 Cesarean scar pregnancy is the rarest form 
of ectopic pregnancy. The first case was described in 1978 
by Larsen and Solomon, and with increased rates of Ce-
sarean sections in recent years, the number of cesarean 
scar pregnancies has increased.3 The estimated incidence 
is from 1 in 1,800 up to 1 in 2,216 pregnancies, with a 
rate of 6.1% of all ectopic pregnancies in women with his-
tory of a previous cesarean section.4,5
Cesarean scar pregnancy can cause catastrophic com-
plications such as uterine rupture progressing with se-
vere, life-threatening bleeding, hysterectomy and end of 
fertility.6 Therefore, early diagnosis performed using trans-
vaginal ultrasound is essential for conservative treatment 
and the preservation of fertility in these patients.
The types of treatment are divided into surgical and 
non-surgical. Surgical treatment may be via uterine cu-
rettage or hysterectomy and also through uterine artery 
embolization. Non-surgical treatment may be expectant, 
medicated with systemic or local methotrexate.
Surgery is the usual conduct; however, due to the risk 
of mutilation, clinical treatment with methotrexate has 
become an important therapeutic alternative.
We report a case that was treated with local injection 
of methotrexate guided by transvaginal ultrasound and 
complemented with multiple courses of systemic meth-
otrexate to reduce the risks of surgery and spare fertility 
in this patient.
Methods
The diagnosis of cesarean scar ectopic pregnancy was per-
formed by transvaginal ultrasound according to the three 
diagnostic criteria described by Vial in 2000:7 the gesta-
tional sac was located between the bladder wall and an-
terior uterine wall, with no fetal part seen inside the uter-
ine cavity. The third criterion was viewed through the 
sagittal section of the uterus in the implantation site of 
the gestational sac, where a discontinuity of myometri-
um in the anterior wall of the uterus was demonstrated.
The patient signed a consent form approved by the Uni-
versidade Federal de São Paulo (Unifesp) Ethics Committee.
Upon confirmation of the diagnosis, the conduct tak-
en followed the protocol of the Unifesp Department of 
Obstetrics for non-tubal ectopic pregnancy, which is wait-
ing when the value of β-hCG is less than 1,500 mIU/mL 
and declining in the interval of 48 hours; drug treatment 
with systemic methotrexate when the embryo does not 
present vitality, with multiple doses if β-hCG is higher 
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than 5,000 mIU/mL, and a single dose if less than 5,000 
mIU/mL; drug treatment with local injection of metho-
trexate guided by transvaginal ultrasound if the embryo 
is alive, with an association made with the protocol for 
multiple dose of systemic methotrexate if the β-hCG val-
ue exceeds 5,000 mIU/mL. In the last treatment option, 
methotrexate is given at a dose of 1 mg/kg, initially with 
local injection, followed by 3 intramuscular doses on al-
ternate days. In the days between these doses, folinic acid 
was administered at a dose of 0.1 mg/kg and control tests 
for possible methotrexate toxicity (hepatic and renal func-
tion), and β-hCG dosage are measured.
In this case report the patient presented a cesarean 
scar ectopic pregnancy with live embryo and β-hCG of 
18,716 mIU/mL. As such, local treatment with transvag-
inal ultrasound-guided injection of methotrexate was in-
dicated, complemented with the protocol of multiple sys-
temic doses of methotrexate.
Post treatment follow-up was done with weekly dos-
ing of β-hCG up to a value of less than 5,000 mIU/mL 
and realization of transvaginal ultrasound until the ab-
sence of the Doppler flow.
case report
The 30-year old pregnant patient, weighing 68 kg, secundi-
gravida, with previous cesarean delivery 12 years before, was 
6 weeks late on her period although presenting a small 
amount of vaginal bleeding for 1 day. On physical exami-
nation the patient was hemodynamically stable; in the spec-
ulum examination there was the presence of vaginal bleed-
ing collected in small quantities; and in the touch 
examination the cervix was impervious, with an increased 
uterus for 6 weeks, and palpable attachments without chang-
es. The laboratory tests were: β-hCG of 18,716, mIU/mL, 
blood test with hemoglobin (Hb) of 12.8 g/dL, hematocrin 
(Ht) of 38.5%, leukocytes of 7,450/uL, platelets of 209,000/
uL, positive O Rh blood typing, 0.57 mg/dL of creatinine, 
urea of 18 mg/dL, SGOT of 26 U/L and SGPT of 28 U/L.
Transvaginal ultrasound performed on this day showed 
a 6 mm crown to rump length (CRL), corresponding to 
gestational age of 6 weeks and 4 days, a gestational sac of 
16 x 14 x 9.6 mm located at the site of the previous cesare-
an section scar with a live embryo (126 bpm fetal heart 
rate), an empty uterine cavity and attachments without 
changes. The gestational sac was located approximately 22 
mm from the external orifice of the cervix (Figure 1).
Due to the presence of the live embryo, the patient 
was submitted to transvaginal ultrasound-guided punc-
ture and injection of methotrexate inside the gestation-
al sac at 68 mg (1 mg/kg). A 17 Gauge Cook® Medical 
needle was used, guided by the Aloka 500® ultrasound 
apparatus.
In addition to the local dose, three 68 mg intramus-
cular doses of methotrexate (1 mg/kg) interspersed with 
4 intramuscular doses of folinic acid at 6.8 mg (0.1 mg/
kg) were given.
The patient remained in hospital until the last dose 
of folinic acid without clinical complications after the 
procedure, showing only slight abdominal colic treated 
with analgesia, receiving a discharge with weekly follow-
up at the outpatient clinic specializing in ectopic preg-
nancy at Hospital São Paulo (Unifesp).
It is important to note that blood test, hepatic and 
renal function examinations remained normal from ad-
mission to discharge from hospital.
Seven days after discharge, the patient sought the 
Gynecology and Obstetrics emergency service of the Hos-
pital São Paulo complaining of vaginal bleeding. In the 
physical examination the patient was found to be hemo-
dynamically stable, the abdominal examination showed 
no changes, the specular examination showed the pres-
ence of a discrete amount of blood collected, painless vag-
inal touch with impervious cervix, and intrapelvic uter-
us and attachments normal to the touch. The laboratory 
examinations on this occasion were still normal (blood, 
hepatic and renal function), showing that there was no 
methotrexate toxicity, with Hb of 12 g/dL and β-hCG of 
6,129 mIU/mL. Another ultrasound examination was per-
formed with uterine volume of 200 cm3 and presence of 
a cystic image on the anterior uterine wall with anecho-
ic content and irregular walls, measuring 1.3 x 1.2 x 0.5 cm, 
without characterization of an embryo, endometrial echo 
of 1.2 cm and unchanged attachments.
FIGURE 1 Ultrasonography showing the anatomical relationship 
between bladder, cervix, uterine body and gestational sac in the 
topography of the cesarean scar, with an empty uterine cavity.
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The patient was advised to continue the outpatient 
follow-up where she remained in weekly monitoring, pro-
gressing with falling β-hCG levels. After 58 days of mon-
itoring, the β-hCG value was negative, as displayed in the 
graph of the progression of this examination (Figure 2). 
After 3 months of treatment with methotrexate, another 
transvaginal ultrasound was conducted, showing the dis-
appearance of the gestational sac (Figure 3).
discussion
Cesarean scar pregnancy is the rarest form of ectopic preg-
nancy. Since the first case described in 1978 until 2001, 
there were only 19 cases reported. By 2006 there were 155 
cases and by 2011 the number of cases described in the 
literature was 751, showing a rapid increase in the inci-
dence of this type of pregnancy.1, 8-11
The basis of the pathophysiology is the invasion of 
the blastocyst in the myometrium through minimal com-
munication between the previous cesarean scar and the 
endometrial cavity.12
The cesarean scar ectopic pregnancy tends to have a 
more aggressive behavior because of the risk of uterine 
rupture and bleeding in the first and second trimesters 
of pregnancy.13
The risk factors are the number of prior cesarean sec-
tions, short time interval between the cesarean delivery 
and the current pregnancy, and retroversion of the uter-
us which may lead to greater cesarean scar dehiscence, in-
creasing the chance of implantation of the gestational 
sac in this region.14
Transvaginal ultrasound allows early diagnosis of this 
disease before tragic outcomes such as uterine rupture 
or excessive bleeding and enables conservative treatment 
instead of mutilating surgeries such as hysterectomy, spar-
ing fertility.7 It also allows differential diagnosis with 
abortion in progress, molar pregnancy and cervical ecto-
pic pregnancy through the ultrasound diagnostic crite-
ria proposed by Vial in 2000.
Vial et al.7 have also proposed two types of cesarean 
scar ectopic pregnancy: endogenous and exogenous. In 
the endogenous type, the implementation of the gesta-
tional sac occurs in the c-section scar with the develop-
ment of the pregnancy into the uterine cavity. The exog-
enous type occurs with deeper implantation of the 
gestational sac in the cesarean scar, which with the pro-
gression of the pregnancy may lead to uterine rupture 
and hemorrhage in the first trimester of pregnancy.
There is still no consensus on the best mode of treat-
ment in the case of cesarean scar ectopic pregnancy. The 
conduct at our service is drug treatment and outpatient 
monitoring with weekly β-hCG exams until resolution, 
only intervening surgically in the presence of heavy bleed-
ing and under these circumstances, if possible, trying to 
perform uterine artery embolization prior to curettage.15
During the outpatient follow-up, the ultrasound ex-
amination is not performed routinely, and should be re-
FIGURE 2 Graph with the progression of β-hCG values in the treatment of the cesarean scar ectopic pregnancy with local and systemic 
methotrexate in this case report.
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peated when β-hCG reaches a negative value or after 3 
months of drug treatment. This should only be brought 
forward if there are new episodes of bleeding.
In our case, a surgical approach was not required, 
using merely drug treatment with a local dose plus three 
local doses of systemic methotrexate. However, a slow re-
gression of β-hCG values was observed to the initially 
high values, taking 58 days to reach negative values. An 
Australian article about 13 cases of cesarean scar ecto-
pic pregnancy suggests that the association of local drug 
treatment with systemic doses can reduce the time in-
terval for β-hCG to become negative and that local meth-
otrexate seems to be more effective than systemic treat-
ment alone due to the presence of fibrotic tissue in the 
region of the scar, limiting the access of systemic medi-
cation.14
After 3 to 6 months of disappearance of the image of 
the ectopic pregnancy, our recommendation is to per-
form hysterosalpingography and hysteroscopy for better 
assessment of the uterine cavity, as well as adequate re-
productive planning for these patients.
conclusion
The early diagnosis of cesarean scar ectopic pregnancy is 
performed via transvaginal ultrasound and is fundamen-
tal for the indication of suitable conservative treatment. 
Drug treatment with a local dose of ultrasound-guided 
methotrexate in the presence of a live embryo, associat-
ed with a protocol of multiple doses of systemic metho-
trexate when β-hCG exceeds 5,000 mIU/mL has been 
found effective, preventing mutilating surgeries and spar-
ing fertility in these patients.
resuMo
Tratamento local com metotrexato guiado por ultrasso-
nografia transvaginal de gravidez ectópica em cicatriz de 
cesárea com embrião vivo: relato de caso
A gravidez ectópica na cicatriz de cesárea é uma forma rara 
de gestação ectópica com elevada morbimortalidade. O em-
prego de condutas conservadoras, como o tratamento me-
dicamentoso com metotrexato, tem evitado cirurgias muti-
ladoras, como a histerectomia, e preservado o futuro 
reprodutivo da mulher. Relatamos um caso de paciente de 
30 anos, com gravidez ectópica em cicatriz de cesárea, com 
embrião vivo, tratada com injeção local de metotrexato guia-
da por ultrassonografia transvaginal, complementada com 
tratamento sistêmico com múltiplas doses de metotrexato.
Palavras-chave: gravidez ectópica, metotrexato, cicatriz, 
cesárea.
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